Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Releases Major CytoSure™ Software Update

Published: Wednesday, April 11, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Microarray analysis tool provides researchers with biologically meaningful results.

Oxford Gene Technology (OGT) has released a major new update to its CytoSure™ Interpret Software for array Comparative Genomic Hybridisation (aCGH) analysis. By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data. For example, samples can be segregated into different projects by sample type or by user, thereby simplifying analysis. It can also perform common analysis steps automatically via the “Accelerate Workflow” mode, which significantly speeds up analysis, especially when working with a large number of samples. The intuitive graphical interface detects DNA regions exhibiting genomic variation, with results presented in an easy-to-use report, annotated with the relevant syndromes, genes, exons, and segmental duplications. This also includes links to external databases, putting each variation in context and helping to highlight the biological implications of the data generated. In addition, this latest software release incorporates a number of cancer annotation tracks, enabling meaningful interpretation of results obtained using OGT’s growing portfolio of CytoSure Cancer arrays.

Dr. Agne Liedén from the Department of Molecular Medicine and Surgery at the Karolinska Institutet, who has recently integrated the new CytoSure Interpret Software into his laboratory’s workflow, commented: “I have been extremely impressed with the ease-of-use and flexibility of the software. In our experience, OGT is very responsive to customer feedback and has produced an excellent software package.” OGT’s CEO, Dr Mike Evans, said: “The new update is part of OGT’s overall strategy, which is dedicated to providing products and services that convert complex datasets into easily interpretable, meaningful results. Our aim is to allow researchers to focus all of their time and energy on investigating the biology, rather than sifting through their data. In this case, constant innovation ensures that our CytoSure Interpret Software remains the industry-leading aCGH analysis software, and our dedicated software development team are continually implementing enhanced features and capabilities in response to customer feedback and new developments in the field.”

To complement OGT’s growing range of proprietary arrays containing both CNV and SNP probes, CytoSure Interpret Software can identify DNA regions exhibiting copy number variation, loss of heterozygosity and mosaicism. The latest update also provides a unique ‘Family Tree’ view, which makes it easy to examine inheritance patterns in up to three generations of the same family. In addition, to further ensure reliable, consistent results, the latest version of CytoSure Interpret Software incorporates permission-based account management. This allows individual users to be assigned specific, customisable access to system functionality and delivers a comprehensive audit trail of any workflow changes, thereby providing consistency of analysis and reporting.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Initiates Clinical Trial of New Array-Based NIPT
Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.
Tuesday, November 04, 2014
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Supports Earlier Lupus Diagnosis
Superior sensitivity and specificity compared to current laboratory tests.
Friday, May 10, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012
The conference will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre.
Friday, February 10, 2012
OGT Founder Professor Sir Ed Southern Awarded the 2011 MRC Millennium Medal
Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis.
Monday, January 30, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Featured in the Sunday Times Biotech Supplement
The article entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations will help push healthcare costs down, while improving the accuracy of early disease diagnosis.
Monday, January 24, 2011
OGT Announces Major Role in Large Scale Diabetes Study
Genefficiency™ aCGH microarray service to process extensive sample set linking CNVs to disease susceptibility.
Thursday, December 02, 2010
OGT Receives ISO/IEC 27001:2005 Accreditation
Certification highlights commitment to information security and confidentiality.
Thursday, September 16, 2010
OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010
Delegates heard presentations on how OGT’s array comparative genomic hybridization solutions can help advance disease and cytogenetics research.
Tuesday, July 13, 2010
Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!